MA38341A1 - Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées - Google Patents

Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées

Info

Publication number
MA38341A1
MA38341A1 MA38341A MA38341A MA38341A1 MA 38341 A1 MA38341 A1 MA 38341A1 MA 38341 A MA38341 A MA 38341A MA 38341 A MA38341 A MA 38341A MA 38341 A1 MA38341 A1 MA 38341A1
Authority
MA
Morocco
Prior art keywords
compositions
methylation modification
modification enzyme
enzyme modulators
modulators
Prior art date
Application number
MA38341A
Other languages
English (en)
Other versions
MA38341B1 (fr
Inventor
Brian Albrecht
James Audia
Andrew Cook
Les Dakin
Martin Duplessis
Victor Gehling
Jean-Christophe Harmange
Christopher Nasveschuk
Rishi Vaswani
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50239937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38341(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/025639 external-priority patent/WO2013120104A2/fr
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of MA38341A1 publication Critical patent/MA38341A1/fr
Publication of MA38341B1 publication Critical patent/MA38341B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des agents ayant la formule structurelle (ii) pour moduler des enzymes de modification par méthylation des histones, des compositions et des utilisations de ceux-ci, par exemple, en tant qu'agents anticancéreux.
MA38341A 2013-02-11 2014-02-11 Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées MA38341B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2013/025639 WO2013120104A2 (fr) 2012-02-10 2013-02-11 Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations
PCT/US2014/015706 WO2014124418A1 (fr) 2013-02-11 2014-02-11 Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées

Publications (2)

Publication Number Publication Date
MA38341A1 true MA38341A1 (fr) 2018-01-31
MA38341B1 MA38341B1 (fr) 2018-11-30

Family

ID=50239937

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38341A MA38341B1 (fr) 2013-02-11 2014-02-11 Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées

Country Status (16)

Country Link
EP (1) EP2953941B1 (fr)
KR (1) KR102219441B1 (fr)
CN (1) CN105102446B (fr)
CL (1) CL2015002239A1 (fr)
CR (1) CR20150457A (fr)
IL (1) IL239985B (fr)
MA (1) MA38341B1 (fr)
ME (1) ME02730B (fr)
PE (1) PE20160044A1 (fr)
PH (1) PH12015501720A1 (fr)
PL (1) PL2953941T3 (fr)
RS (1) RS56207B1 (fr)
SG (1) SG11201506077XA (fr)
SI (1) SI2953941T1 (fr)
TW (1) TWI629273B (fr)
WO (1) WO2014124418A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (fr) 2010-06-23 2020-12-15 Ryan D. Morin Biomarqueurs pour lymphomes non hodgkiniens et leurs utilisations
WO2013075084A1 (fr) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
MX375970B (es) 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
US20180037568A1 (en) * 2015-02-13 2018-02-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US20180214519A1 (en) 2015-07-24 2018-08-02 Constellation Pharmaceuticals, Inc. Combination therapies for modulation of histone methyl modifying enzymes
CA2994394A1 (fr) * 2015-08-03 2017-02-09 Constellation Pharmaceuticals, Inc. Inhibiteurs d'ezh2 et modulation de la fonction des cellules t regulatrices
WO2017035234A1 (fr) 2015-08-24 2017-03-02 Epizyme, Inc. Méthode de traitement du cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (fr) * 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Formes cristallines de (r)-n-((4-méthoxy-6-méthyl-2-oxo-1,2-dihydropyridin-3-yl)méthyl)-2-méthyl-1-(1-(1-(2,2,2-trifluoroéthyl)pipéridin-4-yl)éthyl)-1h-indole-3-carboxamide
WO2017062495A2 (fr) 2015-10-06 2017-04-13 Epizyme, Inc. Procédé de traitement d'un médulloblastome avec un inhibiteur d'ezh2
EP3371601A1 (fr) 2015-11-05 2018-09-12 Epizyme Inc Cytométrie de flux permettant de surveiller l'état de la méthylation d'une histone h3
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
CN105669647B (zh) * 2016-02-22 2018-05-04 上海皓元生物医药科技有限公司 一种组蛋白甲基化酶ezh2抑制剂中间体的合成方法
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
WO2018075598A1 (fr) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthèse d'inhibiteurs d'ezh2
WO2018102687A2 (fr) 2016-12-02 2018-06-07 Epizyme, Inc. Polythérapie pour le traitement du cancer
BR112019014924A2 (pt) 2017-01-19 2020-03-31 St. Marianna University School Of Medicine Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018183885A1 (fr) 2017-03-31 2018-10-04 Epizyme, Inc. Multithérapie pour le traitement du cancer
US20230201212A1 (en) 2017-06-13 2023-06-29 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
US20210161883A1 (en) 2017-07-10 2021-06-03 Constellation Pharmaceuticals, Inc. Ezh2 inhibitor-induced gene expression
WO2019094552A1 (fr) * 2017-11-09 2019-05-16 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
US11529344B2 (en) 2017-11-14 2022-12-20 Pfizer Inc. EZH2 inhibitor combination therapies
CN109879790B (zh) * 2017-12-06 2022-09-20 华东师范大学 以吲哚或吲哚类似物为母核结构的酰胺类小分子有机化合物、用途及其制备方法
CN111757734A (zh) 2017-12-28 2020-10-09 星座制药公司 通过组合疗法的ezh2抑制剂的药代动力学增强
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
CN110229151B (zh) * 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 吲嗪类化合物、其制备方法及用途
CN110229157B (zh) * 2018-03-06 2022-06-21 上海海和药物研究开发股份有限公司 嘧啶并五元芳香杂环类化合物、其制备方法及用途
EP3765458B1 (fr) 2018-03-14 2023-01-11 Biogen MA Inc. Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MX2020010999A (es) 2018-04-18 2021-01-20 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
EP3797108B1 (fr) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulateurs de l'enzyme méthyl modifiant, compositions et leur utilisation.
WO2020011607A1 (fr) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition de sous-unités de prc2 permettant de traiter des troubles oculaires
CN113166137B (zh) 2018-09-19 2024-08-16 比奥根Ma公司 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂
EP4327814A3 (fr) 2018-12-05 2024-04-24 Biogen MA Inc. Dérivés morpholinyle, pipérazinyle, oxazépanyle et diazépanyle en tant qu'inhibiteurs de o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
WO2020139339A1 (fr) 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Inhibiteurs de la signalisation de l'ezh2 et du récepteur des androgènes en tant qu'outils pour le ciblage du cancer de la prostate
AR117989A1 (es) 2019-02-04 2021-09-08 Biogen Ma Inc Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
US12421224B2 (en) 2019-03-08 2025-09-23 Biogen Ma Inc. Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN114269748A (zh) 2019-06-05 2022-04-01 米拉蒂医疗股份有限公司 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物
KR20220041130A (ko) 2019-07-24 2022-03-31 콘스텔레이션 파마슈티칼스, 인크. 암 치료를 위한 병용 요법에서의 ezh2 억제
PE20220562A1 (es) 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
TW202130643A (zh) 2019-10-29 2021-08-16 美商百健Ｍａ公司 螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑
AR123132A1 (es) 2020-08-03 2022-11-02 Biogen Ma Inc Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022150962A1 (fr) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Inhibiteurs de protéase, leur préparation et leurs utilisations
JP7717816B2 (ja) 2021-01-21 2025-08-04 バイオフロント セラピューティクス （ベイジン） カンパニー リミテッド Ｆｐｒ１のモジュレーター及びそれを使用する方法
JP2024517504A (ja) 2021-05-20 2024-04-22 シロナックス リミテッド． アゼチジン環状尿素を含めたｒｉｐ１調節物質、その調製、及び使用
US20250049802A1 (en) 2021-12-14 2025-02-13 Pfizer Inc. Combination therapies and uses for treating cancer
CN118451061A (zh) * 2021-12-20 2024-08-06 费尔黑文制药公司 Oxer1拮抗剂和其用途
JP2025510009A (ja) 2022-02-28 2025-04-14 シロナックス リミテッド． Ｒｉｐ１調節物質、その調製、及び使用
CA3249707A1 (fr) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combinaison d’un conjugué anticorps-médicament avec un inhibiteur de l’ezh1 et/ou de l’ezh2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012012966A (es) * 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
WO2012118812A2 (fr) * 2011-02-28 2012-09-07 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
JO3363B1 (ar) * 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9085583B2 (en) * 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Also Published As

Publication number Publication date
HK1218648A1 (en) 2017-03-03
TWI629273B (zh) 2018-07-11
MA38341B1 (fr) 2018-11-30
PH12015501720B1 (en) 2015-11-09
EP2953941B1 (fr) 2017-04-05
IL239985B (en) 2018-11-29
SI2953941T1 (sl) 2017-08-31
KR20150119201A (ko) 2015-10-23
CN105102446A (zh) 2015-11-25
PL2953941T3 (pl) 2017-11-30
EP2953941A1 (fr) 2015-12-16
IL239985A0 (en) 2015-09-24
ME02730B (fr) 2017-10-20
WO2014124418A1 (fr) 2014-08-14
CR20150457A (es) 2015-10-20
TW201443038A (zh) 2014-11-16
CL2015002239A1 (es) 2016-02-05
RS56207B1 (sr) 2017-11-30
PH12015501720A1 (en) 2015-11-09
SG11201506077XA (en) 2015-08-28
CN105102446B (zh) 2018-01-23
PE20160044A1 (es) 2016-02-11
KR102219441B1 (ko) 2021-02-23

Similar Documents

Publication Publication Date Title
MA38341B1 (fr) Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
MY172156A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MA43187B1 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA47664A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA40534B1 (fr) Inhibiteurs de mk2 et leurs utilisations
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
UA113543C2 (xx) Сполуки та композиції для модулювання egfr активності
EA201790806A1 (ru) Иммунорегулирующие средства
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
MX2013010170A (es) Moduladores heterociclicos de sintesis lipidica.
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
TR201900038T4 (tr) GPR6'nın tetrahidropiridopirazin modülatörleri.
TR201908247T4 (tr) Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri.
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
MX364069B (es) Moduladores de la proteína activadora de 5-lipoxigenasa.
MA44550A1 (fr) Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
MA39337B1 (fr) Modulateurs de pyrazines de gpr6
MA39000B1 (fr) Compositions et méthodes permettant d'inhiber l'expression du gène alas1
TR201203085A2 (tr) Sefetamet ve klavulanik asit içeren bileşimler.
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors
EA202091923A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
TR201002879U (tr) Demirden mamül çok parçalı T bağlantı elemanı.